RxDoctor Payments Data

Steven Fayer, MD

Sports Medicine · New York, NYNPI 1669567640

Payments from drug & device makers

$3,170in general payments, 2019–2025

Across 133 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$978
  • Sunovion Pharmaceuticals Inc.$553
  • Takeda Pharmaceuticals U.S.A., Inc.$549
  • Johnson & Johnson$349
  • Idorsia Pharmaceuticals US Inc$240
  • Bausch Health US, LLC$200
  • plus $303 from 5 others

What the payments were for

  • Food & beverage$3,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,170 in reported general payments places this provider in the 60th percentile of 403 sports medicine providers in New York.

See all sports medicine providers in New York

Medicare billing

Part B allowed, 2024
$79,632
Medicare patients
55
Services billed
808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bupropion XlBupropion Hcl38$1,296
Escitalopram Oxalate61$1,067
Duloxetine Hcl26$1,005
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$852
Clorazepate Dipotassium14$790
Sertraline Hcl37$729
Alprazolam61$719
Lorazepam52$700
Bupropion Hcl SrBupropion Hcl37$640
Fluoxetine Hcl17$618
Clonazepam56$565
Citalopram HbrCitalopram Hydrobromide25$474
Trazodone Hcl48$445
Methylphenidate Hcl28$363
Gabapentin31$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$31$72937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 403 sports medicine providers in New York.

Other sports medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →